checkAd

    DGAP-News  623  0 Kommentare Press Release: 4SC presents new immunotherapeutic activity data of its epigenetic cancer drug resminostat at the ECCO ITOC conference 2015


    DGAP-News: 4SC AG / Key word(s): Research Update
    Press Release: 4SC presents new immunotherapeutic activity data of its
    epigenetic cancer drug resminostat at the ECCO ITOC conference 2015

    26.03.2015 / 07:30

    ---------------------------------------------------------------------

    Press Release

    4SC presents new immunotherapeutic activity data of its epigenetic cancer
    drug resminostat at the ECCO ITOC conference 2015

    Planegg-Martinsried, Germany, 26 March 2015 - 4SC AG (Frankfurt, Prime
    Standard: VSC), a discovery and development company of targeted small
    molecule drugs for cancer and autoimmune diseases, today presents new data
    on immunotherapeutic effects achieved with 4SC's epigenetic cancer drug
    resminostat. The selected presentation will be held today, 26 March 2015,
    11:00am CET at the ECCO ITOC conference 2015 in Munich, Germany.

    The presentation will cover new preclinical data demonstrating
    immunomodulating effects of the HDAC inhibitor resminostat, thus
    potentially further contributing to its anti-tumoral activity, in
    particular enhancing response rates. Resminostat has shown multiple
    positive effects both by re-programming cancer cells and by enhancing the
    immune system's defence mechanism against cancer cells.

    The data indicate the ability of resminostat to help considerably improve
    the effect of checkpoint inhibitors (PD1/PDL1) and other immunotherapeutic
    approaches in oncology such as antibodies (e.g. rituximab) or
    immunostimulating agents (e.g. TLR ligands), when applied in combination
    therapy with these drugs in the clinic.

    Dr Daniel Vitt, Chief Scientific Officer and Chief Development Officer of
    4SC, said: "We are highly excited about the new data demonstrating multiple
    immunotherapeutic effects of our lead oncology product resminostat. We
    believe that this data potentially opens up new avenues for safe and
    efficacious combination therapies with immune checkpoint inhibitors and
    immunotherapeutic antibodies. We are currently further evaluating the data
    in animal models and we are excited to be creating potential further
    clinical options in the future."

    The scientific findings in detail

    Resminostat effects on mechanisms affecting anti-tumoral immune responses
    were analysed in hepatocellular HepG2, Huh7, and SNU475 and adenocarcinomic
    A549 cellular systems. It was shown that resminostat strongly reduced the
    expression of immunosuppression mediating enzymes, IDO1 and ARG1 thus
    Seite 1 von 4


    EQS Group AG
    0 Follower
    Autor folgen

    Verfasst von EQS Group AG
    DGAP-News Press Release: 4SC presents new immunotherapeutic activity data of its epigenetic cancer drug resminostat at the ECCO ITOC conference 2015 DGAP-News: 4SC AG / Key word(s): Research Update Press Release: 4SC presents new immunotherapeutic activity data of its epigenetic cancer drug resminostat at the ECCO ITOC conference 2015 26.03.2015 / 07:30 …